Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial
Purpose To compare the effects of combined oral contraceptives (OCs) containing cyproterone acetate and drospirenone in the treatment of polycystic ovary syndrome (PCOS). Methods Fifty-two patients with PCOS were randomized in two groups: group A ( n = 26) received 0.035 mg ethinyl estradiol + 2 mg...
Gespeichert in:
| Veröffentlicht in: | Archives of gynecology and obstetrics 2014-08, Vol.290 (2), p.321-328 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 328 |
|---|---|
| container_issue | 2 |
| container_start_page | 321 |
| container_title | Archives of gynecology and obstetrics |
| container_volume | 290 |
| creator | Kahraman, Korhan Şükür, Yavuz Emre Atabekoğlu, Cem Somer Ateş, Can Taşkın, Salih Çetinkaya, Şerife Esra Tolunay, Harun Egemen Özmen, Batuhan Sönmezer, Murat Berker, Bülent |
| description | Purpose
To compare the effects of combined oral contraceptives (OCs) containing cyproterone acetate and drospirenone in the treatment of polycystic ovary syndrome (PCOS).
Methods
Fifty-two patients with PCOS were randomized in two groups: group A (
n
= 26) received 0.035 mg ethinyl estradiol + 2 mg cyproterone acetate and group B (
n
= 26) received 0.03 mg ethinyl estradiol + 3 mg drospirenone-containing OCs for 12 months. Baseline clinical features including body mass index, waist to hip ratio (WHR), and modified Ferriman-Gallwey (mFG) score were noted. Baseline biochemical parameters included androgen profile, carbohydrate metabolism, lipid profile, and oxidative stress. The percentages of changes for all parameters were compared.
Results
The groups were comparable regarding the baseline characteristics. WHR decreased significantly from baseline (−4 % [−31 to 35]) in group B when compared to group A (0 % [−11 to 14]) (
P
= 0.033). The total mFG score decreased significantly from baseline (−35 % [−71 to 10]) in group A when compared to group B (−18 % [−72 to 30]) (
P
= 0.035). Changes in androgen hormone profile were comparable except DHEA-SO
4
(−32 % [−53 to 15] in group B vs. −10 % [−49 to 63] in group A;
P
= 0.046). The effects of the drugs were similar regarding carbohydrate metabolism, lipid profile, and oxidative stress parameters.
Conclusions
Cyproterone acetate containing OCs seem to be more effective to treat clinical hirsutism in patients with PCOS after 12 months of treatment. |
| doi_str_mv | 10.1007/s00404-014-3217-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1546221358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2261875612</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-8a137a9e3d9180bf47ae648c078abb6de88939b58dac30ccba3592c7d58c60283</originalsourceid><addsrcrecordid>eNp1kctu1TAQhi1ERQ-FB2CDLLFhE-pbbIcdOioXqVI3sLYcZ9K6Suxg-7QKr8UL4nAKSEhdzcjzzT8z_hF6Rck7Sog6z4QIIhpCRcMZVU37BO2o4KwhitKnaEe6LSdSnaLnOd8SQpnW8hk6ZUIqKTuxQz_3cV5s8jkGHEdc7iOOyU7YxVCSdbAUfwd4jGnOv9-sDz5cY7cuKRZIMQCuVLGlxjDgIcW8-ARhK_iAyw3gksCWGULZBiy2-JpmfO_LDV7itLo1F-9wvLNpxXkNVWKG99jiVAXj7H_AgN1Ux7q6VkneTi_QyWinDC8f4hn69vHi6_5zc3n16cv-w2XjhGCl0ZZyZTvgQ0c16UehLEihHVHa9r0cQOuOd32rB-s4ca63vO2YU0OrnSRM8zP09qhbb_1-gFzM7LODabIB4iEb2grJGOXthr75D72NhxTqdoYxSbVqJWWVokfK1W_KCUazJD_Xuw0lZnPUHB011VGzOWra2vP6QfnQzzD87fhjYQXYEci1FK4h_Rv9uOovtTqwjw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2261875612</pqid></control><display><type>article</type><title>Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Kahraman, Korhan ; Şükür, Yavuz Emre ; Atabekoğlu, Cem Somer ; Ateş, Can ; Taşkın, Salih ; Çetinkaya, Şerife Esra ; Tolunay, Harun Egemen ; Özmen, Batuhan ; Sönmezer, Murat ; Berker, Bülent</creator><creatorcontrib>Kahraman, Korhan ; Şükür, Yavuz Emre ; Atabekoğlu, Cem Somer ; Ateş, Can ; Taşkın, Salih ; Çetinkaya, Şerife Esra ; Tolunay, Harun Egemen ; Özmen, Batuhan ; Sönmezer, Murat ; Berker, Bülent</creatorcontrib><description>Purpose
To compare the effects of combined oral contraceptives (OCs) containing cyproterone acetate and drospirenone in the treatment of polycystic ovary syndrome (PCOS).
Methods
Fifty-two patients with PCOS were randomized in two groups: group A (
n
= 26) received 0.035 mg ethinyl estradiol + 2 mg cyproterone acetate and group B (
n
= 26) received 0.03 mg ethinyl estradiol + 3 mg drospirenone-containing OCs for 12 months. Baseline clinical features including body mass index, waist to hip ratio (WHR), and modified Ferriman-Gallwey (mFG) score were noted. Baseline biochemical parameters included androgen profile, carbohydrate metabolism, lipid profile, and oxidative stress. The percentages of changes for all parameters were compared.
Results
The groups were comparable regarding the baseline characteristics. WHR decreased significantly from baseline (−4 % [−31 to 35]) in group B when compared to group A (0 % [−11 to 14]) (
P
= 0.033). The total mFG score decreased significantly from baseline (−35 % [−71 to 10]) in group A when compared to group B (−18 % [−72 to 30]) (
P
= 0.035). Changes in androgen hormone profile were comparable except DHEA-SO
4
(−32 % [−53 to 15] in group B vs. −10 % [−49 to 63] in group A;
P
= 0.046). The effects of the drugs were similar regarding carbohydrate metabolism, lipid profile, and oxidative stress parameters.
Conclusions
Cyproterone acetate containing OCs seem to be more effective to treat clinical hirsutism in patients with PCOS after 12 months of treatment.</description><identifier>ISSN: 0932-0067</identifier><identifier>EISSN: 1432-0711</identifier><identifier>DOI: 10.1007/s00404-014-3217-5</identifier><identifier>PMID: 24676694</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adolescent ; Adult ; Androgen Antagonists - therapeutic use ; Androgens ; Androgens - blood ; Androstenes - therapeutic use ; Biomarkers - blood ; Body Mass Index ; Carbohydrate Metabolism ; Clinical trials ; Contraceptives, Oral, Combined - administration & dosage ; Contraceptives, Oral, Combined - therapeutic use ; Cyproterone Acetate - therapeutic use ; Endocrinology ; Estrogens - therapeutic use ; Ethinyl Estradiol - therapeutic use ; Female ; General Gynecology ; Gynecology ; Human Genetics ; Humans ; Lipids - blood ; Medicine ; Medicine & Public Health ; Metabolism ; Mineralocorticoid Receptor Antagonists - therapeutic use ; Obstetrics/Perinatology/Midwifery ; Oxidative Stress ; Polycystic ovary syndrome ; Polycystic Ovary Syndrome - drug therapy ; Treatment Outcome ; Turkey ; Waist-Hip Ratio</subject><ispartof>Archives of gynecology and obstetrics, 2014-08, Vol.290 (2), p.321-328</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>Archives of Gynecology and Obstetrics is a copyright of Springer, (2014). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-8a137a9e3d9180bf47ae648c078abb6de88939b58dac30ccba3592c7d58c60283</citedby><cites>FETCH-LOGICAL-c442t-8a137a9e3d9180bf47ae648c078abb6de88939b58dac30ccba3592c7d58c60283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00404-014-3217-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00404-014-3217-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24676694$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kahraman, Korhan</creatorcontrib><creatorcontrib>Şükür, Yavuz Emre</creatorcontrib><creatorcontrib>Atabekoğlu, Cem Somer</creatorcontrib><creatorcontrib>Ateş, Can</creatorcontrib><creatorcontrib>Taşkın, Salih</creatorcontrib><creatorcontrib>Çetinkaya, Şerife Esra</creatorcontrib><creatorcontrib>Tolunay, Harun Egemen</creatorcontrib><creatorcontrib>Özmen, Batuhan</creatorcontrib><creatorcontrib>Sönmezer, Murat</creatorcontrib><creatorcontrib>Berker, Bülent</creatorcontrib><title>Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial</title><title>Archives of gynecology and obstetrics</title><addtitle>Arch Gynecol Obstet</addtitle><addtitle>Arch Gynecol Obstet</addtitle><description>Purpose
To compare the effects of combined oral contraceptives (OCs) containing cyproterone acetate and drospirenone in the treatment of polycystic ovary syndrome (PCOS).
Methods
Fifty-two patients with PCOS were randomized in two groups: group A (
n
= 26) received 0.035 mg ethinyl estradiol + 2 mg cyproterone acetate and group B (
n
= 26) received 0.03 mg ethinyl estradiol + 3 mg drospirenone-containing OCs for 12 months. Baseline clinical features including body mass index, waist to hip ratio (WHR), and modified Ferriman-Gallwey (mFG) score were noted. Baseline biochemical parameters included androgen profile, carbohydrate metabolism, lipid profile, and oxidative stress. The percentages of changes for all parameters were compared.
Results
The groups were comparable regarding the baseline characteristics. WHR decreased significantly from baseline (−4 % [−31 to 35]) in group B when compared to group A (0 % [−11 to 14]) (
P
= 0.033). The total mFG score decreased significantly from baseline (−35 % [−71 to 10]) in group A when compared to group B (−18 % [−72 to 30]) (
P
= 0.035). Changes in androgen hormone profile were comparable except DHEA-SO
4
(−32 % [−53 to 15] in group B vs. −10 % [−49 to 63] in group A;
P
= 0.046). The effects of the drugs were similar regarding carbohydrate metabolism, lipid profile, and oxidative stress parameters.
Conclusions
Cyproterone acetate containing OCs seem to be more effective to treat clinical hirsutism in patients with PCOS after 12 months of treatment.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Androgens</subject><subject>Androgens - blood</subject><subject>Androstenes - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Body Mass Index</subject><subject>Carbohydrate Metabolism</subject><subject>Clinical trials</subject><subject>Contraceptives, Oral, Combined - administration & dosage</subject><subject>Contraceptives, Oral, Combined - therapeutic use</subject><subject>Cyproterone Acetate - therapeutic use</subject><subject>Endocrinology</subject><subject>Estrogens - therapeutic use</subject><subject>Ethinyl Estradiol - therapeutic use</subject><subject>Female</subject><subject>General Gynecology</subject><subject>Gynecology</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Lipids - blood</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Mineralocorticoid Receptor Antagonists - therapeutic use</subject><subject>Obstetrics/Perinatology/Midwifery</subject><subject>Oxidative Stress</subject><subject>Polycystic ovary syndrome</subject><subject>Polycystic Ovary Syndrome - drug therapy</subject><subject>Treatment Outcome</subject><subject>Turkey</subject><subject>Waist-Hip Ratio</subject><issn>0932-0067</issn><issn>1432-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kctu1TAQhi1ERQ-FB2CDLLFhE-pbbIcdOioXqVI3sLYcZ9K6Suxg-7QKr8UL4nAKSEhdzcjzzT8z_hF6Rck7Sog6z4QIIhpCRcMZVU37BO2o4KwhitKnaEe6LSdSnaLnOd8SQpnW8hk6ZUIqKTuxQz_3cV5s8jkGHEdc7iOOyU7YxVCSdbAUfwd4jGnOv9-sDz5cY7cuKRZIMQCuVLGlxjDgIcW8-ARhK_iAyw3gksCWGULZBiy2-JpmfO_LDV7itLo1F-9wvLNpxXkNVWKG99jiVAXj7H_AgN1Ux7q6VkneTi_QyWinDC8f4hn69vHi6_5zc3n16cv-w2XjhGCl0ZZyZTvgQ0c16UehLEihHVHa9r0cQOuOd32rB-s4ca63vO2YU0OrnSRM8zP09qhbb_1-gFzM7LODabIB4iEb2grJGOXthr75D72NhxTqdoYxSbVqJWWVokfK1W_KCUazJD_Xuw0lZnPUHB011VGzOWra2vP6QfnQzzD87fhjYQXYEci1FK4h_Rv9uOovtTqwjw</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>Kahraman, Korhan</creator><creator>Şükür, Yavuz Emre</creator><creator>Atabekoğlu, Cem Somer</creator><creator>Ateş, Can</creator><creator>Taşkın, Salih</creator><creator>Çetinkaya, Şerife Esra</creator><creator>Tolunay, Harun Egemen</creator><creator>Özmen, Batuhan</creator><creator>Sönmezer, Murat</creator><creator>Berker, Bülent</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20140801</creationdate><title>Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial</title><author>Kahraman, Korhan ; Şükür, Yavuz Emre ; Atabekoğlu, Cem Somer ; Ateş, Can ; Taşkın, Salih ; Çetinkaya, Şerife Esra ; Tolunay, Harun Egemen ; Özmen, Batuhan ; Sönmezer, Murat ; Berker, Bülent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-8a137a9e3d9180bf47ae648c078abb6de88939b58dac30ccba3592c7d58c60283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Androgens</topic><topic>Androgens - blood</topic><topic>Androstenes - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Body Mass Index</topic><topic>Carbohydrate Metabolism</topic><topic>Clinical trials</topic><topic>Contraceptives, Oral, Combined - administration & dosage</topic><topic>Contraceptives, Oral, Combined - therapeutic use</topic><topic>Cyproterone Acetate - therapeutic use</topic><topic>Endocrinology</topic><topic>Estrogens - therapeutic use</topic><topic>Ethinyl Estradiol - therapeutic use</topic><topic>Female</topic><topic>General Gynecology</topic><topic>Gynecology</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Lipids - blood</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Mineralocorticoid Receptor Antagonists - therapeutic use</topic><topic>Obstetrics/Perinatology/Midwifery</topic><topic>Oxidative Stress</topic><topic>Polycystic ovary syndrome</topic><topic>Polycystic Ovary Syndrome - drug therapy</topic><topic>Treatment Outcome</topic><topic>Turkey</topic><topic>Waist-Hip Ratio</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kahraman, Korhan</creatorcontrib><creatorcontrib>Şükür, Yavuz Emre</creatorcontrib><creatorcontrib>Atabekoğlu, Cem Somer</creatorcontrib><creatorcontrib>Ateş, Can</creatorcontrib><creatorcontrib>Taşkın, Salih</creatorcontrib><creatorcontrib>Çetinkaya, Şerife Esra</creatorcontrib><creatorcontrib>Tolunay, Harun Egemen</creatorcontrib><creatorcontrib>Özmen, Batuhan</creatorcontrib><creatorcontrib>Sönmezer, Murat</creatorcontrib><creatorcontrib>Berker, Bülent</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kahraman, Korhan</au><au>Şükür, Yavuz Emre</au><au>Atabekoğlu, Cem Somer</au><au>Ateş, Can</au><au>Taşkın, Salih</au><au>Çetinkaya, Şerife Esra</au><au>Tolunay, Harun Egemen</au><au>Özmen, Batuhan</au><au>Sönmezer, Murat</au><au>Berker, Bülent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial</atitle><jtitle>Archives of gynecology and obstetrics</jtitle><stitle>Arch Gynecol Obstet</stitle><addtitle>Arch Gynecol Obstet</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>290</volume><issue>2</issue><spage>321</spage><epage>328</epage><pages>321-328</pages><issn>0932-0067</issn><eissn>1432-0711</eissn><abstract>Purpose
To compare the effects of combined oral contraceptives (OCs) containing cyproterone acetate and drospirenone in the treatment of polycystic ovary syndrome (PCOS).
Methods
Fifty-two patients with PCOS were randomized in two groups: group A (
n
= 26) received 0.035 mg ethinyl estradiol + 2 mg cyproterone acetate and group B (
n
= 26) received 0.03 mg ethinyl estradiol + 3 mg drospirenone-containing OCs for 12 months. Baseline clinical features including body mass index, waist to hip ratio (WHR), and modified Ferriman-Gallwey (mFG) score were noted. Baseline biochemical parameters included androgen profile, carbohydrate metabolism, lipid profile, and oxidative stress. The percentages of changes for all parameters were compared.
Results
The groups were comparable regarding the baseline characteristics. WHR decreased significantly from baseline (−4 % [−31 to 35]) in group B when compared to group A (0 % [−11 to 14]) (
P
= 0.033). The total mFG score decreased significantly from baseline (−35 % [−71 to 10]) in group A when compared to group B (−18 % [−72 to 30]) (
P
= 0.035). Changes in androgen hormone profile were comparable except DHEA-SO
4
(−32 % [−53 to 15] in group B vs. −10 % [−49 to 63] in group A;
P
= 0.046). The effects of the drugs were similar regarding carbohydrate metabolism, lipid profile, and oxidative stress parameters.
Conclusions
Cyproterone acetate containing OCs seem to be more effective to treat clinical hirsutism in patients with PCOS after 12 months of treatment.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>24676694</pmid><doi>10.1007/s00404-014-3217-5</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0932-0067 |
| ispartof | Archives of gynecology and obstetrics, 2014-08, Vol.290 (2), p.321-328 |
| issn | 0932-0067 1432-0711 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1546221358 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Adult Androgen Antagonists - therapeutic use Androgens Androgens - blood Androstenes - therapeutic use Biomarkers - blood Body Mass Index Carbohydrate Metabolism Clinical trials Contraceptives, Oral, Combined - administration & dosage Contraceptives, Oral, Combined - therapeutic use Cyproterone Acetate - therapeutic use Endocrinology Estrogens - therapeutic use Ethinyl Estradiol - therapeutic use Female General Gynecology Gynecology Human Genetics Humans Lipids - blood Medicine Medicine & Public Health Metabolism Mineralocorticoid Receptor Antagonists - therapeutic use Obstetrics/Perinatology/Midwifery Oxidative Stress Polycystic ovary syndrome Polycystic Ovary Syndrome - drug therapy Treatment Outcome Turkey Waist-Hip Ratio |
| title | Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T00%3A04%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20two%20oral%20contraceptive%20forms%20containing%20cyproterone%20acetate%20and%20drospirenone%20in%20the%20treatment%20of%20patients%20with%20polycystic%20ovary%20syndrome:%20a%20randomized%20clinical%20trial&rft.jtitle=Archives%20of%20gynecology%20and%20obstetrics&rft.au=Kahraman,%20Korhan&rft.date=2014-08-01&rft.volume=290&rft.issue=2&rft.spage=321&rft.epage=328&rft.pages=321-328&rft.issn=0932-0067&rft.eissn=1432-0711&rft_id=info:doi/10.1007/s00404-014-3217-5&rft_dat=%3Cproquest_cross%3E2261875612%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2261875612&rft_id=info:pmid/24676694&rfr_iscdi=true |